- Home
- KPRX vs CODX Comparison
KPRX vs CODX Comparison
Compare KPRX & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- CODX
- Stock Information
- Founded
- KPRX 1998
- CODX 2013
- Country
- KPRX United States
- CODX United States
- Employees
- KPRX N/A
- CODX N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CODX Medical/Dental Instruments
- Sector
- KPRX Health Care
- CODX Health Care
- Exchange
- KPRX Nasdaq
- CODX Nasdaq
- Market Cap
- KPRX 8.7M
- CODX 9.8M
- IPO Year
- KPRX N/A
- CODX 2017
- Fundamental
- Price
- KPRX $2.93
- CODX $0.29
- Analyst Decision
- KPRX Strong Buy
- CODX Buy
- Analyst Count
- KPRX 1
- CODX 2
- Target Price
- KPRX $10.00
- CODX $5.50
- AVG Volume (30 Days)
- KPRX 93.7K
- CODX 5.0M
- Earning Date
- KPRX 08-08-2025
- CODX 08-14-2025
- Dividend Yield
- KPRX N/A
- CODX N/A
- EPS Growth
- KPRX N/A
- CODX N/A
- EPS
- KPRX N/A
- CODX N/A
- Revenue
- KPRX N/A
- CODX $1,003,653.00
- Revenue This Year
- KPRX N/A
- CODX N/A
- Revenue Next Year
- KPRX N/A
- CODX $42.11
- P/E Ratio
- KPRX N/A
- CODX N/A
- Revenue Growth
- KPRX N/A
- CODX N/A
- 52 Week Low
- KPRX $2.25
- CODX $0.23
- 52 Week High
- KPRX $4.29
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- KPRX 59.57
- CODX 63.33
- Support Level
- KPRX $2.27
- CODX $0.24
- Resistance Level
- KPRX $2.60
- CODX $0.27
- Average True Range (ATR)
- KPRX 0.18
- CODX 0.02
- MACD
- KPRX 0.03
- CODX 0.00
- Stochastic Oscillator
- KPRX 89.47
- CODX 40.83
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.